Hereditary haemochromatosis

Best Practice and Research: Clinical Gastroenterology

Volumn 23, Issue 2, 2009, Pages 171-183

  Janssen, M C H ^a   Swinkels, D W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

diagnosis; ferritin; hereditary haemochromatosis; screening

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DEFERASIROX; DEFERIPRONE; FERRITIN; HEPCIDIN; HFE PROTEIN; PROTON PUMP INHIBITOR;

APHERESIS; ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG MECHANISM; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HEMOCHROMATOSIS; HEREDITARY HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; LIVER BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHLEBOTOMY; RISK FACTOR;

GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; MEMBRANE PROTEINS; MUTATION; PATIENT SELECTION; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 65349116544     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2009.02.004     Document Type: Article

References (83)

1. Merryweather-Clarke A.T., Pointon J.J., Jouanolle A.M., et al. Geography of HFE C282Y and H63D mutations. Genet Test 4 2 (2000) 183-198
2. Adams P.C., and Barton J.C. Haemochromatosis. Lancet 370 9602 (2007 Dec 1) 1855-1860
3. Niederau C., Fischer R., Purschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110 4 (1996 Apr) 1107-1119
4. Feder J.N., Gnirke A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13 4 (1996 Aug) 399-408
5. Feder J.N. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res 20 2 (1999) 175-185
6. Swinkels D.W., Janssen M.C., Bergmans J., et al. Hereditary hemochromatosis: genetic complexity and new diagnostic approaches. Clin Chem 52 6 (2006 Jun) 950-968
7. Olynyk J.K., Trinder D., Ramm G.A., et al. Hereditary hemochromatosis in the post-HFE era. Hepatology 48 3 (2008 Sep) 991-1001
8. Nicolas G., Viatte L., Bennoun M., et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 29 3 (2002 Nov) 327-335
9. Bridle K.R., Frazer D.M., Wilkins S.J., et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 361 9358 (2003 Feb 22) 669-673
10. Kemna E.H., Tjalsma H., Willems H.L., et al. Hepcidin: from discovery to differential diagnosis. Haematologica 93 1 (2008 Jan) 90-97
11. Piperno A., Girelli D., Nemeth E., et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 110 12 (2007 Dec 1) 4096-4100
12. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110 7 (2002 Oct) 1037-1044
13. Pak M., Lopez M.A., Gabayan V., et al. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108 12 (2006 Dec 1) 3730-3735
14. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 5704 (2004 Dec 17) 2090-2093
15. Ahmad K.A., Ahmann J.R., Migas M.C., et al. Decreased liver hepcidin expression in the Hfe knockout mouse. Blood Cells Mol Dis 29 3 (2002 Nov) 361-366
16. van Dijk B.A., Laarakkers C.M., Klaver S.M., et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 142 6 (2008 Sep) 979-985
17. Koppenol W.H. The centennial of the Fenton reaction. Free Radic Biol Med 15 6 (1993 Dec) 645-651
18. Koppenol W.H. The Haber-Weiss cycle-70 years later. Redox Rep 6 4 (2001) 229-234
19. Harrison-Findik D.D., Schafer D., Klein E., et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem 281 32 (2006 Aug 11) 22974-22982
20. Wood M.J., Powell L.W., and Ramm G.A. Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111 9 (2008 May 1) 4456-4462
21. Adams P.C., Kertesz A.E., and Valberg L.S. Clinical presentation of hemochromatosis: a changing scene. Am J Med 90 4 (1991 Apr) 445-449
22. Adams P.C., Deugnier Y., Moirand R., et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology 25 1 (1997 Jan) 162-166
23. Bacon B.R., and Sadiq S.A. Hereditary hemochromatosis: presentation and diagnosis in the 1990s. Am J Gastroenterol 92 5 (1997 May) 784-789
24. Elmberg M., Hultcrantz R., Ekbom A., et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125 6 (2003 Dec) 1733-1741
25. McDonnell S.M., Preston B.L., Jewell S.A., et al. A survey of 2851 patients with hemochromatosis: symptoms and response to treatment. Am J Med 106 6 (1999 Jun) 619-624
26. McDermott J.H., and Walsh C.H. Hypogonadism in hereditary hemochromatosis. J Clin Endocrinol Metab 90 4 (2005 Apr) 2451-2455
27. Whitlock E.P., Garlitz B.A., Harris E.L., et al. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 145 3 (2006 Aug 1) 209-223
28. Swinkels D.W., Jorna A.T., and Raymakers R.A. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med 65 11 (2007 Dec) 452-455
29. Qaseem A., Aronson M., Fitterman N., et al. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 143 7 (2005 Oct 4) 517-521
30. Schmitt B., Golub R.M., and Green R. Screening primary care patients for hereditary hemochromatosis with transferrin saturation and serum ferritin level: systematic review for the American College of Physicians. Ann Intern Med 143 7 (2005 Oct 4) 522-536
31. Tavill A.S. Diagnosis and management of hemochromatosis. Hepatology 33 5 (2001 May) 1321-1328
32. Harrison-Findik D.D. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 13 37 (2007 Oct 7) 4925-4930
33. Mendler M.H., Turlin B., Moirand R., et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 117 5 (1999 Nov) 1155-1163
34. Ismail A.R., Lachlan K.L., Mumford A.D., et al. Hereditary hyperferritinemia cataract syndrome: ocular, genetic, and biochemical findings. Eur J Ophthalmol 16 1 (2006 Jan) 153-160
35. Girelli D., Bozzini C., Zecchina G., et al. Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia-cataract syndrome. Br J Haematol 115 2 (2001 Nov) 334-340
36. Roeckel I.E., and Dickson L.G. Understanding iron absorption and metabolism, aided by studies of hemochromatosis. Ann Clin Lab Sci 28 1 (1998 Jan) 30-33
37. Waalen J., Nordestgaard B.G., and Beutler E. The penetrance of hereditary hemochromatosis. Best Pract Res Clin Haematol 18 2 (2005 Jun) 203-220
38. Deugnier Y., and Turlin B. Pathology of hepatic iron overload. World J Gastroenterol 13 35 (2007 Sep 21) 4755-4760
39. Falize L., Guillygomarc'h A., Perrin M., et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 44 2 (2006 Aug) 472-477
40. Gandon Y., Olivie D., Guyader D., et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363 9406 (2004 Jan 31) 357-362
41. Pietrangelo A. Non-invasive assessment of hepatic iron overload: are we finally there?. J Hepatol 42 1 (2005 Jan) 153-154
42. Guyader D., Gandon Y., Robert J.Y., et al. Magnetic resonance imaging and assessment of liver iron content in genetic hemochromatosis. J Hepatol 15 3 (1992 Jul) 304-308
43. St Pierre T.G., Clark P.R., Chua-Anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 2 (2005 Jan 15) 855-861
44. Pietrangelo A., Corradini E., Ferrara F., et al. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol Dis 37 3 (2006 Nov) 192-196
45. Adhoute X., Foucher J., Laharie D., et al. Diagnosis of liver fibrosis using FibroScan and other noninvasive methods in patients with hemochromatosis: a prospective study. Gastroenterol Clin Biol 32 2 (2008 Feb) 180-187
46. Nguyen-Khac E., and Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol 18 12 (2006 Dec) 1321-1325
47. Wojcik J.P., Speechley M.R., Kertesz A.E., et al. Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 16 5 (2002 May) 297-302
48. Brissot P. Diagnosis and current treatments for primary iron overload. Am J Hematol 82 12 Suppl. (2007 Dec) 1140-1141
49. Bozzini C., Campostrini N., Trombini P., et al. Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells Mol Dis 40 3 (2008 May) 347-352
50. Muncunill J., Vaquer P., Galmes A., et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher 17 2 (2002) 88-92
51. Mariani R., Pelucchi S., Perseghin P., et al. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 90 5 (2005 May) 717-718
52. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 83 5 (2008 May) 398-402
53. Barton J.C. Chelation therapy for iron overload. Curr Gastroenterol Rep 9 1 (2007 Mar) 74-82
54. Bring P., Partovi N., Ford J.A., et al. Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy 28 3 (2008 Mar) 331-342
55. Hutchinson C., Geissler C.A., Powell J.J., et al. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 56 9 (2007 Sep) 1291-1295
56. Hutchinson C., Conway R.E., Bomford A., et al. Post-prandial iron absorption in humans: comparison between HFE genotypes and iron deficiency anaemia. Clin Nutr 27 2 (2008 Apr) 258-263
57. Ludwiczek S., Theurl I., Muckenthaler M.U., et al. Ca2+ channel blockers reverse iron overload by a new mechanism via divalent metal transporter-1. Nat Med 13 4 (2007 Apr) 448-454
58. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 350 23 (2004 Jun 3) 2383-2397
59. Pointon J.J., Merryweather-Clarke A.T., Carella M., et al. Detection of C282Y and H63D in the HFE gene. Genet Test 4 2 (2000) 115-120
60. Swinkels D.W., Venselaar H., Wiegerinck E.T., et al. A novel (Leu183Pro-)mutation in the HFE-gene co-inherited with the Cys282Tyr mutation in two unrelated Dutch hemochromatosis patients. Blood Cells Mol Dis 40 3 (2008 May) 334-338
61. Papanikolaou G., Samuels M.E., Ludwig E.H., et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36 1 (2004 Jan) 77-82
62. Njajou O.T., Alizadeh B.Z., and van Duijn C.M. Is genetic screening for hemochromatosis worthwhile?. Eur J Epidemiol 19 2 (2004) 101-108
63. Drakesmith H., Schimanski L.M., Ormerod E., et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106 3 (2005 Aug 1) 1092-1097
64. Kato J., Fujikawa K., Kanda M., et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 69 1 (2001 Jul) 191-197
65. Watkins S., Thorburn D., Joshi N., et al. The biochemical and clinical penetrance of individuals diagnosed with genetic haemochromatosis by predictive genetic testing. Eur J Gastroenterol Hepatol 20 5 (2008 May) 379-383
66. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood 101 9 (2003 May 1) 3347-3350
67. Andersen R.V., Tybjaerg-Hansen A., Appleyard M., et al. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103 8 (2004 Apr 15) 2914-2919
68. Adams P.C., Reboussin D.M., Barton J.C., et al. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study. Int J Lab Hematol 30 4 (2008 Aug) 300-305
69. Powell L.W., Dixon J.L., and Hewett D.G. Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol 18 2 (2005 Jun) 221-234
70. Pietrangelo A. The penetrance of hemochromatosis: mice to the rescue. Gastroenterology 132 2 (2007 Feb) 805-808
71. Gurrin L.C., Osborne N.J., Constantine C.C., et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 135 6 (2008 Sep 13) 1945-1952
72. Allen K.J., Gurrin L.C., Constantine C.C., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med 358 3 (2008 Jan 17) 221-230
73. Ellervik C., Birgens H., Tybjaerg-Hansen A., et al. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 46 4 (2007 Oct) 1071-1080
74. Olynyk J.K., St Pierre T.G., Britton R.S., et al. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol 100 4 (2005 Apr) 837-841
75. Olynyk J.K., Cullen D.J., Aquilia S., et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341 10 (1999 Sep 2) 718-724
76. Olynyk J.K., Hagan S.E., Cullen D.J., et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin Proc 79 3 (2004 Mar) 309-313
77. Beutler E., Felitti V.J., Koziol J.A., et al. Penetrance of 845 G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 359 9302 (2002 Jan 19) 211-218
78. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet 349 9048 (1997 Feb 1) 296-297
79. Burke W., Imperatore G., McDonnell S.M., et al. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2 5 (2000 Sep) 271-277
80. Lyon E., and Frank E.L. Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem 47 7 (2001) 1147-1156
81. Mura C., Raguenes O., Scotet V., et al. A 6-year survey of HFE gene test for hemochromatosis diagnosis. Genet Med 7 1 (2005 Jan) 68-73
82. Phatak P.D., Bonkovsky H.L., and Kowdley K.V. Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 149 4 (2008 Aug 19) 270-272
83. Gagne G., Reinharz D., Laflamme N., et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet 71 1 (2007 Jan) 46-58